News headlines about Ophthotech Corporation (NASDAQ:OPHT) have been trending positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ophthotech Corporation earned a news impact score of 0.34 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 92 out of 100, meaning that recent news coverage is extremely likely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern’s rankings:

Shares of Ophthotech Corporation (NASDAQ:OPHT) traded up 1.296% during mid-day trading on Tuesday, hitting $2.735. 188,381 shares of the stock were exchanged. The stock’s 50-day moving average price is $2.57 and its 200-day moving average price is $3.63. Ophthotech Corporation has a 52-week low of $2.24 and a 52-week high of $65.96. The company’s market cap is $98.06 million.

Ophthotech Corporation (NASDAQ:OPHT) last posted its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.20) earnings per share for the quarter, beating the consensus estimate of ($1.31) by $0.11. The firm had revenue of $1.66 million for the quarter, compared to analysts’ expectations of $1.94 million. Equities research analysts anticipate that Ophthotech Corporation will post ($3.88) earnings per share for the current fiscal year.

Separately, Zacks Investment Research raised shares of Ophthotech Corporation from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a report on Tuesday, May 2nd. Twelve investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $53.53.

TRADEMARK VIOLATION WARNING: “Ophthotech Corporation (OPHT) Given News Sentiment Rating of 0.34” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at

In other news, Chairman David R. Guyer sold 17,678 shares of Ophthotech Corporation stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $2.58, for a total transaction of $45,609.24. Following the completion of the transaction, the chairman now directly owns 37,692 shares of the company’s stock, valued at approximately $97,245.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 34,609 shares of company stock valued at $89,249. Insiders own 2.00% of the company’s stock.

About Ophthotech Corporation

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech Corporation (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.